Anifrolumab (Saphnelo) listed in NS

March 6, 2024 – Lupus Canada is pleased to share that Saphnelo has been listed in Nova Scotia effective March 1, 2024.

The public notice and listing criteria will appear on the Nova Scotia Pharmacare Programs website when the March Bulletin is posted.

Lupus Blog Articles:

Lupus Treatment and Access Across Provinces: Take the Patient Survey

Read

Let’s Talk Lupus: Stories from Canadians Living with Lupus

Read

Canada Disability Benefit Regulations Finalized | What It Means for Lupus Patients

Read